

Review

The Role of Phosphorylation and Acylation in the Regulation of Drug Resistance in *Mycobacterium tuberculosis*

Manluan Sun ^{1,2,*}, Sai Ge ^{2,3} and Zhaoyang Li ⁴¹ School of Medicine, Shanxi Datong University, Datong 037009, China² Institute of Carbon Materials Science, Shanxi Datong University, Datong 037009, China³ Center of Academic Journal, Shanxi Datong University, Datong 037009, China⁴ Laboratory of Molecular Biology, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA

* Correspondence: manluansun@163.com

Abstract: Tuberculosis is a chronic and lethal infectious disease caused by *Mycobacterium tuberculosis*. In previous decades, most studies in this area focused on the pathogenesis and drug targets for disease treatments. However, the emergence of drug-resistant strains has increased the difficulty of clinical trials over time. Now, more post-translational modified proteins in *Mycobacterium tuberculosis* have been discovered. Evidence suggests that these proteins have the ability to influence tuberculosis drug resistance. Hence, this paper systematically summarizes updated research on the impacts of protein acylation and phosphorylation on the acquisition of drug resistance in *Mycobacterium tuberculosis* through acylation and phosphorylation protein regulating processes. This provides us with a better understanding of the mechanism of antituberculosis drugs and may contribute to a reduction the harm that tuberculosis brings to society, as well as aiding in the discovery of new drug targets and therapeutic regimen adjustments in the future.

Keywords: *Mycobacterium tuberculosis*; acylation; phosphorylation; post-translational modification; drug-resistance

Citation: Sun, M.; Ge, S.; Li, Z. The Role of Phosphorylation and Acylation in the Regulation of Drug Resistance in *Mycobacterium tuberculosis*. *Biomedicines* **2022**, *10*, 2592. <https://doi.org/10.3390/biomedicines10102592>

Academic Editor: Amirata Saei Dibavar

Received: 15 August 2022

Accepted: 14 October 2022

Published: 15 October 2022

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Tuberculosis (TB) is a chronic and fatal disease caused by *Mycobacterium tuberculosis* (MTB). According to the World Health Organization (WHO), drug-resistant TB can be classified into five types. Single-drug-resistant TB is only resistant to one of the first-line anti-TB drugs. Poly-drug-resistant TB is resistant to more than one front-line anti-TB drug other than isoniazid (INH) and rifampicin (RIF). Multidrug-resistant (MDR) TB is resistant to both INH and RIF at least. Pan-drug-resistant TB is resistant not only to INH, RIF, and fluoroquinolones (FQs) but also to all second-line anti-TB drug injections. RIF-resistant (RR) TB is regarded as resistant to RIF, whether it is resistant to other drugs or not [1]. Although medicines have been used in clinical trials, the emergence of drug-resistant TB has caused the treatments to become unsatisfactory. Moreover, undergoing 18–30 months of clinical therapy increases the possibility of drug resistance occurring, which makes it even harder for patients to fully recover [2,3]. It is estimated that 9.9 million people were affected by TB worldwide in 2021, and the number of affected people may continuously increase in the foreseeable future [1]. The rising number of affected patients brings a heavy burden to both families and society. Hence, a better understanding of the drug-resistant mechanism associated with MTB will directly contribute to TB prevention and treatment in the future.

Early studies indicate that MTB is naturally resistant to many antibiotics because of its special cell structure and metabolic enzymes [4]. For example, differential gene expres-

sion or mutation could lead to changes in drug targets [5,6]. Changes in the MTB membrane permeability or drug intake/efflux pump may decrease the concentration of intracellular antibiotics [7]. However, studies in this area were more focused on the developments of drug resistance or drug targets in MTB [5–7]. Post-translational modifications (PTMs) were discovered in about one-third of all MTB proteins. These modified proteins are involved in almost all aspects of intracellular physiological activities, regulating the growth process, metabolism, gene expression, and virulence of MTB [8–11]. Recently, more and more data have been collected to suggest that PTMs may have impacts on tuberculosis drug resistance [8–11]. This paper systematically summarizes updated research on the impacts of protein acylation and phosphorylation on the acquisition of drug resistance by MTB through acylated and phosphorylated protein regulating processes.

2. Lys Acylation

2.1. Acetylation

N-acetylation is a dynamic and reversible post-translational modification. It plays a role in various regulation pathways of MTB. Conventional acetylation is often catalyzed by acetyltransferase (also known as acetylase). Meanwhile, some proteins have been identified as directly acetylated by acetyl donors (such as acetyl co-enzyme A or acetyl phosphate) without enzymes [12]. In contrast, protein deacetylation generally requires deacetylase to catalyze deacetylation [13]. In MTB, the enhanced intracellular survival (Eis) protein is an acetyltransferase that acetylates a second-line anti-TB drug, such as kanamycin (Figure 1). Meanwhile, the overexpression of the *eis* gene in MTB inactivates the antimicrobial function of kanamycin [14]. However, strains obtained from the clinical environment with the *eis* promoter mutation could reduce the kanamycin tolerance [14,15]. In addition, Eis can inactivate capreomycin antibacterial activity by acetylation [16]. On the other hand, a proteome analysis indicated that the Eis protein itself undergoes acetylation modification [17]. Hence, research on Eis mostly focuses on the screening of its inhibitors. However, the following questions remain unclear and should be answered: Does Eis affect the drug action by acetylating proteins in the process of drug tolerance metabolism? Is there a regulating process between the acetylation of Eis itself and aminoglycoside antibiotics resistance?




Figure 1. Connections of anti-tuberculosis drugs resistance and protein acylation in MTB. Ac, acetylation; Eis, enhanced intracellular survival protein; FQs, fluoroquinolones; GyrA/B, gyrase subunit A/B protein, INH, isoniazid; KAN, kanamycin; LZD, linezolid; Suc, succinylation.

With the rapid development of proteomics, more and more acetylated proteins in MTB have been identified. Among these acetylated proteins, quite a few were found to be related to drug tolerance. For example, data suggest that PknH, PhoP, MurF, KatG, InhA, RpoB, RpsL, GyrA, and GyrB may have impacts on the resistance of INH, ethambutol (EMB), FQs, kanamycin, and vancomycin [11,18]. However, whether the acetylation is related to the antibiotic resistance is still unclear. In the present study, the putative acetyltransferase Rv2710 in MTB is reported to inactivate INH. The overexpression of Rv2710 in *M. tuberculosis* H37Ra leads to its resistance to INH at MICs [19].

HupB is not only an essential iron regulatory protein for the growth of MTB [20]; it is also a histone-like protein. It can bind to DNA to regulate the expression of the mycobacterial genome [21]. HupB can be regulated by lysine methylation and lysine acetylation, which have a relationship with bacterial phenotypical drug-resistance [22]. The acetylation of HupB at Lys86 can affect the expression of corresponding genes, resulting in INH-resistance in the mycobacterium [22]. In addition, when HupB Lys86 is acetylated by Eis, the binding of HupB to DNA will be affected [23]. However, the relationship between this modification affection and drug-resistant acquisition remains unclear and needs to be further studied.

The expression of the molecular chaperone protein GroEL in MTB is induced under environmental drug pressure, which helps other proteins fold correctly to resist drug pressure. Transcriptome and proteome data show that when MTB is exposed to linezolid (LZD), streptomycin, ofloxacin and/or other antibiotics, the expression of the molecular chaperone GroEL2 increases significantly [24,25]. Meanwhile, data suggest that GroEL2 has multiple acetylated sites, including Lys33, Lys140 and Lys195, but whether those acetylated sites affect drug-resistant acquisition remains unclear and needs to be further studied [17].

2.2. Succinylation

Succinylation is a new PTM that was discovered in recent years. It describes the transfer of succinyl group(s) to lysine residues through enzymatic or non-enzymatic catalysis [26]. A succinylated proteome of XDR strains was identified in China for the first time in 2014. InhA, RopB, and GyrA/GyrB were found to be succinylated and related to anti-TB drug targets [27]. Among these proteins, GyrA/GyrB is the target protein of the second line anti-TB drug FQs. Succinylation at Lys523 of GyrB forms a similar spatial structure to the natural mutations A515T or A515V [28], which is related to the tolerance of FQs in MTB. These studies indicate that succinylation is related to FQs resistance through modifying GyrA/GyrB.

Another catalase, KatG, can activate INH and mediate the sensitivity of MTB to INH [29]. The succinylation of KatG at the Lys310 site reduces the sensitivity of MTB to INH, resulting in an increase in INH MIC by 200-fold [11,27,30]. Moreover, the 410th and 688th lysine residues were identified as having the ability to be acetylated, but their significance in drug resistance remains unknown.

3. Ser/Thr/Tyr Phosphorylation

Reversible protein phosphorylation plays an important role in the response to external pressure for MTB [31]. In MTB, there are 11 kinds of eukaryotic-like Ser/Thr protein kinases (STPKs, including PknA-PknK), 1 homologous phosphatase, 1 tyrosine kinase and 2 tyrosine phosphatases [32–34]. These kinases regulate the phosphorylation of intracellular proteins which, in turn, affects the cell growth and division, gene expression, protein synthesis, pathogenicity and drug resistance of MTB [35–37]. All of these processes would also influence the anti-TB drug metabolism in cells.

3.1. Phosphorylation of Proteins Related to Cell Wall Synthesis

Similarly to most bacteria, the synthesis of MTB cell walls is a dynamic process, which can profoundly and sensitively respond to environmental stresses. Serine/threonine protein kinase B (PknB) is not only an essential protein involved in regulating MTB cell wall synthesis, it is also a potential anti-tuberculosis drug target (Figure 2A) [38]. Among the substrate proteins phosphorylated by PknB, both CwlM and PonA1 are involved in mycobacterial cell wall formation [39–41]. CwlM is a peptidoglycan hydrolase (amidase) that is responsible for the hydrolysis of bacterial cell walls [42]. Together with UDP-N-acetylglucosamine enolpyruvyl transferase (MurA), the enzyme involved in the first step of the synthesis of peptidoglycan, CwlM regulates the biosynthesis of peptidoglycan [42–44]. PknB can activate the overexpression of MurA and cell division by phosphorylating CwlM under a rich nutritional environment for MTB growth. Actively dividing mycobacteria are more sensitive to antibiotics such as INH and RIF, compared with cells that are not living in rich nutritional environments [25]. In *Mycobacterium smegmatis*, CwlM is the substrate of Ser/Thr phosphatase PstP. The site-directed mutation (T171E) of PstP, which mimics the phosphorylation of PstP, can affect the antibiotic resistance of bacteria in the growth and lag phases [45]. However, whether the true phosphorylation state in MTB affects drug resistance requires more experimental data.




Figure 2. Connections of anti-tuberculosis drugs resistance and protein phosphorylation in MTB. (A) PknB mediates drug resistance/tolerance by phosphorylation; (B) Regulation of STPK genes after treatment with anti-tuberculosis drugs. EF-Tu, elongation factor Tu; EMB, ethambutol; ETO,

ethionamide; GTP, guanosine-5-triphosphate; INH, isoniazid; InhA, 2-*trans*-enoyl-acyl carrier protein reductase; MabA, beta-ketoacyl-acyl carrier protein reductase; MurA, UDP-N-acetylglucosamine enolpyruvate transferase; NAD⁺, nicotinamide adenine dinucleotide; P, phosphorylation; RIF, rifampicin; STPK, Ser/Thr protein kinase; SahH, S-adenosyl homocysteine hydrolase.

PonA1 is a penicillin-binding protein that is essential for the maintenance of cell wall biosynthesis and cell shape during MTB growth. PonA1 can perform two activities: transglycosylation and transpeptidation. In MTB and *Mycobacterium smegmatis*, the transpeptidase activity of PonA1 is mostly related to the resistance of antibiotics targeting cell wall synthesis, such as penicillin V and meropenem [46]. The transglycoside activity of PonA1 will be regulated when PonA1 is phosphorylated by PknB at Thr34. This phosphorylation process can affect the balance between these two enzymatic activities of PonA1, which leads to a difference in the antibiotic sensitivity of mycobacteria [41]. Meanwhile, a four-fold increase in the sensitivity to the glycopeptide antibiotic teicoplanin was discovered with a lack of phosphorylation of PonA1 [41]. Therefore, PknB can affect the sensitivity of mycobacteria to antibiotics by regulating the activity of PonA1 through phosphorylation.

The specific components of the MTB cell wall make its drug resistance mechanisms unique and different from those of other bacteria. In MTB, various proteins have been identified as targets of numerous drugs [37,47–49], which participate in the process of mycolic acid biosynthesis (Figure 3). Fatty acid synthase typeII (FAS-II) is a multi-enzyme system that is a target associated with the inhibition of mycolic acid synthesis by drugs in MTB [50]. The active INH Beta-ketoacyl-acyl carrier protein reductase (MabA) and NADH-specific enoyl acyl carrier protein reductase (InhA) are important enzymes associated with FAS-II [51,52]. The activated INH inhibits the InhA protein by binding to its active site which, in turn, hinders mycolic acid synthesis, and disturbs *M. tuberculosis* cell wall biosynthesis [19]. MabA and InhA can be phosphorylated by many kinds of STPKs, including PknB. Three phosphorylated threonine sites in MabA have been identified, of which Thr191 is the main phosphorylation residue, while for InhA, Thr66 is the main phosphorylation site [53–55]. Phosphorylation of MabA and InhA reduces their enzymatic activities, resulting in a decrease in mycolic acid synthesis and a change in cell wall permeability [56]. Additionally, the *mabA*^{g609a} silent mutation results in the upregulation of *inhA*, which may be a novel mechanism associated with INH tolerance [57]. Similarly, MabA and/or InhA are targets of INH and ethionamide (ETO). When MTB is treated with INH/ETO, the expression and function of MabA and/or InhA is inhibited [58]. Why do two different treatment methods have similar effects? Whether the phosphorylation of MabA and InhA is related to the mechanisms associated with INH and ETO drug effects remains to be further studied.




Figure 3. Biosynthesis of mycolic acid in *Mycobacterium tuberculosis*. Ac-CoA, acetyl-coenzyme A; FAS-I, fatty acid synthase type I; HadABC, beta-hydroxyacyl-ACP dehydratase complex; InhA, 2-trans-enoyl-acyl carrier protein reductase; KasA/KasB, beta-ketoacyl-acyl carrier protein synthases A/B; MabA, beta-ketoacyl-acyl carrier protein reductase.

Other important components of the FAS-II system are the beta-ketoacyl carrier protein synthases (KasA and KasB, as shown in Figure 3). They complete the synthesis of the beta-ketoacyl carrier protein (ACP) together [59]. Studies have shown that KasA and KasB participate in the formation of INH resistance by MTB. Through chemical genetic screening, KasB is upregulated by RIF, INH, ETO, vancomycin, and meropenem [60]. KasA and KasB can be phosphorylated by many kinds of STPKs, and their activities decrease after phosphorylation, for example, to MabA and InhA. Meanwhile, mass spectrometry and site-directed mutagenesis show that phosphorylation, or its mimic state of KasB, at the Thr334 or/and Thr336 sites affects the pathogenicity and acid-fast staining of MTB [61]. Therefore, it is speculated that the inhibition of phosphorylation by enzymatic activity regulates the sensitivity of MTB to those drugs.

3.2. Phosphorylation of Proteins Related to DNA Metabolism and Transcription

Different from the mechanism by which other bacteria acquire antibiotic resistance through horizontal gene transfer, one of the main mechanisms of drug resistance of MTB is the change in important genes in drug targets and metabolic pathways, including the DNA damage response (DDR) [5,62]. In MTB, LexA is one of the important regulators involved in DDR. RecA, a DNA-dependent ATP enzyme, regulates repair in DDR by interacting with LexA. In the DDR process of MTB, phosphorylation of RecA at Ser207 leads to its inactivation and inhibits its binding process with the LexA repressor. Phosphorylation aggravates DNA damage and is responsible for this inhibition, making MTB resistant to RIF [63].

Data suggest that some phosphorylation transcription factors also participate in the change in MTB drug-resistance. Ethambutol, a first-line anti-TB drug, inhibits the activity of arabinosyltransferase and blocks the synthesis of arabinogalactan. This inhibition reg-

ulates the ratio of lipoarabinomannan (LAM) to lipomannan (LM), thereby changing bactericidal effects by affecting the permeability of the cell wall [64]. The EmbR transcription factor regulates the *embCAB* operon, which contains three consecutive genes encoding for arabinosyltransferase. On the other hand, STPKs such as PknA, PknB, and PknH can phosphorylate EmbR to promote its binding with DNA. Hence, the phosphorylation processes increase the transcription of *embCAB* and change the resistance to EMB [65,66].

Ethionamide (ETO), a second-line oral drug for the clinical treatment of tuberculosis, needs to be activated by the monooxygenase EthA to perform intracellular functions [67]. MTB increases its resistance to ETO when the transcription inhibitor EthR binds to the *ethA-ethR* area to inhibit the expression of *ethA*, resulting in a reduction in EthA activity [68]. On the other hand, the N-terminal of EthR can be phosphorylated by the kinase PknF at Thr2, Thr3, Ser4 and Ser7. The site-directed mutation of these amino acid residues, which mimics phosphorylation, can reduce the affinity of EthR to DNA, resulting in the inhibition of *ethA* caused by EthR reduction [69]. Therefore, phosphorylation may regulate the ETO resistance of MTB by affecting the relationship between EthR and EthA. However, the specific regulatory mechanisms need more data for confirmation.

3.3. Phosphorylation of Proteins Related to Translation

In the process of protein translation, the elongation factor Tu (EF-Tu) delivers aminoacyl-tRNA to the ribosome. Proteomics data show that EF-Tu can be phosphorylated by PknB to reduce the interaction between EF-Tu and GTP, resulting in a reduction in the efficiency of protein translation [70,71]. When EF-Tu is phosphorylated, MTB shows lower sensitivity to kirromycin [71]. Moreover, some researchers have found that the expression of EF-Tu decreases when MTB is treated with INH. Meanwhile, compared with common MTB strains, the expression of EF-Tu from anti-norfloxacin MTB increased twofold. However, the impact of EF-Tu expression and phosphorylation processes remains unclear.

3.4. Phosphorylation of Proteins That Participate in Other Biological Processes

MTB regulates the activities of proteins that participate in important metabolism pathways through phosphorylation to adapt to environmental changes. More and more studies are indicating that these enzymes are the targets of anti-TB drugs. Among them, the levels of protein metabolism related homocysteine, S-adenosylmethionine (SAM), and S-adenosylhomocysteine (SAH) are regulated by S-adenosylhomocysteine hydrolase (SahH). The reversible hydrolysis of SAH by SahH needs the assistance of NAD⁺ [72]. It has been shown that the phosphokinase PknB from MTB can phosphorylate SahH at the Thr219, Thr220, and Thr221 residues. These phosphorylated residues are found in the active sites of the enzyme. Phosphorylation processes reduce the affinity of SahH and NAD⁺ and subsequently influence the levels of products in homocysteine metabolism [73]. It has also been reported that SahH is one of the binding proteins associated with the INH-NAD(P) complex. Its phosphorylation processes may affect the interaction between SahH and INH as well as influencing the resistance of MTB to INH [74].

3.5. STPKs Involved in Drug Resistance

By analyzing the transcriptome reported in MTB research, we found that the *pknA* gene is downregulated 4.76-, 2.11-, and 2.14-fold after treatment with capreomycin, amikacin and streptomycin, respectively. Meanwhile, the *pknB* gene is downregulated 3.41-fold after treatment with tetracycline. In contrast, following the treatment with roxithromycin and streptomycin, the *pknJ* gene is upregulated 2.14- and 2-fold, respectively. With RIF treatment, the *pknE* gene is upregulated 5.2-fold, and the *pknG* gene is upregulated 2.71-fold following treatment with INH (Figure 2B) [75]. PknG is one of the most important STPKs in MTB. Antibiotic sensitivity was shown to increase in the MTB and *Mycobacterium smegmatis* *pknG* deletion mutant strains [76]. Instead, after the complementary *pknG* experiment, the drug resistance was restored. However, the drug resistance could

not be recovered by complementing with the PknG^{K181M} mutant [77]. Hence, as an important protein kinase in MTB, whether PknG can change the drug resistance by regulating the phosphorylation of its substrate is also one of the research topics for the future.

PknG regulates the central carbon and nitrogen metabolism by regulating the phosphorylation levels of its substrates, which are often related to drug resistance in MTB [78–81]. Another well-studied substrate of PknG is the GarA protein. GarA can regulate the TCA cycle and nitrogen metabolism negatively by binding to the α -ketoglutarate dehydrogenase complex (KDH). GarA contains a phosphorylation recognition FHA (forkhead-associated) domain [82]. The phosphorylation of GarA reduces its inhibitory effects on KDH [83]. Studies have shown that phosphorylated GarA combines with α -ketoglutarate decarboxylase (KGD), NAD-dependent glutamate deoxy-enzyme (GDH) as well as glutamate synthase (GS) and affects their activities. These enzymes regulated by GarA are involved in the interconversion between NAD⁺ and NADH. Therefore, PknG may affect the intracellular NADH pool by regulating the phosphorylation of GarA. On the other hand, in MTB, intracellular oxidative stress is closely related to drug metabolism and resistance, for example, INH and ETO. Hence, PknG may affect the drug tolerance of MTB by regulating the levels of NADH and free radicals that result in cell death [84–86].

Interestingly, acetylation processes have been identified in some STPKs, such as PknD, PknK, PknG, and PknH [11,87]. Moreover, EmbR, which plays an important role in EMB resistance, can be phosphorylated by PknH as well as being modified by acetylation. In addition, those two types of protein modification are also found in Wag31, which is an essential protein and a drug target in MTB [88]. In MDR strains, the expression of Wag31 is upregulated. The site-direct mutant (Q201R) of Wag31 mimics the deacetylated protein, which has been proven to be related to the drug resistance of amino pyrimidine sulfonamide (APYS1) [89]. However, whether acetylation and phosphorylation can double regulate important proteins related to the tolerance of anti-TB drugs is also an interesting research direction for the future.

4. Summary and Prospect

With the rapid developments in mass spectrometry, transcriptome and chemotherapy (pharmacomics), more and more post-translational modified proteins of MTB have been identified. Some post-translational modifications originally found only in eukaryotes are gradually appearing in prokaryotes. Acylation and phosphorylation proteins regulate the cell status by becoming involved in almost all aspects of intracellular physiological activities (Table 1). Due to the emergence of drug-resistant tuberculosis, research on its mechanism in MTB has gradually become a hot topic in scientific research.

Table 1. Common phosphorylated and/or acylated proteins involved in drug-resistance in MTB.

Protein	Functions	Post-Translational Modifications	Related Antibiotics-Resistance
KatG	catalase peroxidase, INH-resistance	Phosphorylation, acetylation, succinylation	INH
MetK	S-adenosylmethionine synthase, decreased expression after INH treatment	Phosphorylation, acetylation	INH
InhA	Enoyl Acyl carrier protein reductase, inhA transcription change after INH treatment	Phosphorylation, acetylation	INH
MabA	Beta-ketoacyl-acyl carrier protein reductase, participate in INH tolerance together with InhA	Phosphorylation, acetylation	INH

EF-Tu	elongation factor Tu, decreased expression after INH treatment	Phosphorylation, acetylation	INH, kirromycin
KasA and KasB	beta-ketoacyl carrier protein synthases	Phosphorylation	INH, RIF, ETO
HupB	essential regulatory protein, Lys acetylation results in INH resistance	Acetylation, lysine methylation	INH
SahH	S-adenosylhomocysteine hydrolase, INH-NADP complex will be affected after its phosphorylation	Phosphorylation, acetylation	INH
EmbR	transcription factor for embCAB, tolerance to EMB will be changed by its phosphorylation	Phosphorylation, acetylation	EMB
RecA and LexA	phosphorylation of RecA inhibits its binding with LexA repressor	Phosphorylation	RIF
GyrA and GyrB	DNA gyrase	Succinylation, phosphorylation	FQs
GroEL2	molecular chaperone protein, increased expression after LZD, streptomycin, ofloxacin treatment	Phosphorylation, acetylation	LZD, streptomycin, ofloxacin
Eis	enhanced intracellular survival protein	Acetylation	kanamycin, capreomycin
EthA	monooxygenase	Acetylation	ETO
EthR	EthA transcriptional regulator	Phosphorylation	ETO
PonA1	penicillin-binding protein, transglycoside activity of PonA1 will be regulated by phosphorylation	Phosphorylation	penicillin V, meropenem

Although there is a significant body of research on the mechanism by which drug resistance occurs in MTB, research on the roles of acylation and phosphorylation is still in the initial stage. In recent years, acylation and phosphorylation have been identified in large number of proteins in clinical isolates (including standard strains and drug-resistant strains) of MTB [90]. For example, Birhanu et al. found that 953 proteins in MTB are acetylated, and these modified proteins participate in bacterial center metabolism, oxidative stress, environmental pressure and antibiotic tolerance [11]. Xie et al. found that phosphorylated proteins in MTB participate in drug resistance, bacterial virulence, and interactions with the host [31]. Meanwhile, with the extensive use of antibiotics in the treatment of tuberculosis, bacteria evolve to have new and more complex drug resistance mechanisms so that they can quickly perceive drug pressure and regulate their transcription, translation, metabolism, and corresponding enzyme functions. Acylation and phosphorylation, as the most common PTMs, play important regulatory roles in the above processes. However, there are still many unsolved problems. For instance, the previously discussed iron regulatory protein HupB of MTB can be regulated by multiple post-translational modifications, such as acetylation, phosphorylation and methylation. It is known that the acetylation of HupB affects the sensitivity of MTB to INH, but its specific processes are still unclear. At present, research on PTMs is focused on single modifications, but whether modifications regulate and influence each other is also a topic worthy of future discussion.

Author Contributions: Conceptualization, M.S. and S.G.; methodology, M.S. and S.G.; software, M.S. and Z.L.; validation, M.S.; formal analysis, M.S. and S.G.; investigation, M.S. and S.G.; resources, M.S. and S.G.; data curation, M.S., Z.L. and S.G.; writing—original draft preparation, M.S. and S.G.; writing—review and editing, M.S. and S.G.; visualization, M.S. and S.G.; supervision, M.S.; project administration, M.S.; funding acquisition, M.S. and S.G. All authors have read and agreed to the published version of the manuscript.

Funding: This Research project was supported by the Shanxi Scholarship Council of China (2022-175); the Fundamental Research Program of Shanxi Province (202103021223339; 20210302124435); the Science and Technology Innovation Project of Universities in Shanxi Province (2019L0773; 2019L0771); and the Scientific Research Foundation for Ph.D. by Shanxi Datong University (2018-B-28; 2018-B-13).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: This research project was supported by the Shanxi Scholarship Council of China (2022-175); the Fundamental Research Program of Shanxi Province (202103021223339; 20210302124435); the Science and Technology Innovation Project of Universities in Shanxi Province (2019L0773; 2019L0771); and the Scientific Research Foundation for Ph.D. by Shanxi Datong University (2018-B-28; 2018-B-13).

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Organization, W.H. *Global Tuberculosis Report 2021*; WHO: Geneva, Switzerland, 2021.
2. Alffenaar, J.; Stocker, S.; Forsman, L.D.; Garcia-Prats, A.; Heysell, S.; Aarnoutse, R.; Akkerman, O.; Aleksa, A.; van Altena, R.; de Oñata, W.A. Clinical standards for the dosing and management of TB drugs. *Int. J. Tuberc. Lung Dis.* **2022**, *26*, 483–499. <https://doi.org/10.5588/ijtld.22.0188>.
3. Zheng, X.; Forsman, L.D.; Bao, Z.; Xie, Y.; Ning, Z.; Schön, T.; Bruchfeld, J.; Xu, B.; Alffenaar, J.-W.; Hu, Y. Drug exposure and susceptibility of second-line drugs correlate with treatment response in patients with multidrug-resistant tuberculosis: A multicentre prospective cohort study in China. *Eur. J. Respir. Med.* **2022**, *59*, 2101925. <https://doi.org/10.1183/13993003.01925-2021>.
4. Te Brake, L.H.; de Knecht, G.J.; de Steenwinkel, J.E.; Van Dam, T.J.; Burger, D.M.; Russel, F.G.; van Crevel, R.; Koenderink, J.B.; Aarnoutse, R.E. The role of efflux pumps in tuberculosis treatment and their promise as a target in drug development: Unraveling the black box. *Annu. Rev. Pharmacol. Toxicol.* **2018**, *58*, 271–291. <https://doi.org/10.1146/annurev-pharmtox-010617-052438>.
5. Gillespie, S.H. Evolution of drug resistance in *Mycobacterium tuberculosis*: Clinical and molecular perspective. *Antimicrob. Agents Chemother.* **2002**, *46*, 267–274. <https://doi.org/10.1128/AAC.46.2.267-274.2002>.
6. Gygli, S.M.; Borrell, S.; Trauner, A.; Gagneux, S. Antimicrobial resistance in *Mycobacterium tuberculosis*: Mechanistic and evolutionary perspectives. *FEMS Microbiol. Rev.* **2017**, *41*, 354–373. <https://doi.org/10.1093/femsre/fux011>.
7. Buriánková, K.; Doucet-Populaire, F.; Dorson, O.; Gondran, A.; Ghnassia, J.-C.; Weiser, J.; Pernodet, J.-L. Molecular basis of intrinsic macrolide resistance in the *Mycobacterium tuberculosis* complex. *Antimicrob. Agents Chemother.* **2004**, *48*, 143–150. <https://doi.org/10.1128/AAC.48.1.143-150.2004>.
8. Kandpal, M.; Aggarwal, S.; Jamwal, S.; Yadav, A.K. Emergence of drug resistance in mycobacteria and other bacterial pathogens: The posttranslational modification perspective. In *Drug Resistance in Bacteria, Fungi, Malaria, and Cancer*; Springer: Berlin, Germany; Heidelberg, Germany, 2017; pp. 209–231.
9. Arora, G.; Bothra, A.; Prosser, G.; Arora, K.; Sajid, A. Role of post-translational modifications in the acquisition of drug resistance in *Mycobacterium tuberculosis*. *FEBS J.* **2021**, *288*, 3375–3393. <https://doi.org/10.1111/febs.15582>.
10. Naledi, K.C.; Nel, A.J.; Garnett, S.; Blackburn, J.M.; Soares, N.C. Comparative Ser/Thr/Tyr phosphoproteomics between two mycobacterial species: The fast growing *Mycobacterium smegmatis* and the slow growing *Mycobacterium bovis* BCG. *Front. Microbiol.* **2015**, *6*, 237. <https://doi.org/10.3389/fmicb.2015.00237>.
11. Birhanu, A.G.; Yimer, S.A.; Holm-Hansen, C.; Norheim, G.; Aseffa, A.; Abebe, M.; Tønnum, T. Nε- and O-Acetylation in *Mycobacterium tuberculosis* lineage 7 and lineage 4 strains: Proteins involved in bioenergetics, virulence, and antimicrobial resistance are acetylated. *J. Proteome. Res.* **2017**, *16*, 4045–4059. <https://doi.org/10.1021/acs.jproteome.7b00429>.
12. Manluan, S.; Hongsen, G.; Guoliang, L.; Jing, G.; Xude, W.; Xian-En, Z.; Jiaoyu, D. Lysine acetylation regulates the activity of *Escherichia coli* S-adenosylmethionine synthase. *Acta Biochim. Biophys. Sin.* **2016**, *48*, 723–731. <https://doi.org/10.1093/abbs/gmw066>.
13. James, A.M.; Hoogewijs, K.; Logan, A.; Hall, A.R.; Ding, S.; Fearnley, I.M.; Murphy, M.P. Non-enzymatic N-acetylation of lysine residues by acetylCoA often occurs via a proximal S-acetylated thiol intermediate sensitive to glyoxalase II. *Cell Rep.* **2017**, *18*, 2105–2112. <https://doi.org/10.1016/j.celrep.2017.02.018>.

14. Punetha, A.; Green, K.D.; Garzan, A.; Chandrika, N.T.; Willby, M.J.; Pang, A.H.; Hou, C.; Holbrook, S.Y.; Krieger, K.; Posey, J.E. Structure-based design of haloperidol analogues as inhibitors of acetyltransferase Eis from *Mycobacterium tuberculosis* to overcome kanamycin resistance. *RSC Med. Chem.* **2021**, *12*, 1894–1909. <https://doi.org/10.1039/d1md00239b>.
15. Zaunbrecher, M.A.; Sikes, R.D.; Metchock, B.; Shinnick, T.M.; Posey, J.E. Overexpression of the chromosomally encoded aminoglycoside acetyltransferase eis confers kanamycin resistance in *Mycobacterium tuberculosis*. *Proc. Natl. Acad. Sci. USA* **2009**, *106*, 20004–20009. <https://doi.org/10.1073/pnas.0907925106>.
16. Houghton, J.L.; Green, K.D.; Pricer, R.E.; Mayhoub, A.S.; Garneau-Tsodikova, S. Unexpected N-acetylation of capreomycin by mycobacterial Eis enzymes. *J. Antimicrob. Chemother.* **2013**, *68*, 800–805. <https://doi.org/10.1093/jac/dks497>.
17. Bi, J.; Wang, Y.; Yu, H.; Qian, X.; Wang, H.; Liu, J.; Zhang, X. Modulation of central carbon metabolism by acetylation of isocitrate lyase in *Mycobacterium tuberculosis*. *Sci. Rep.* **2017**, *7*, 44826. <https://doi.org/10.1038/srep44826>.
18. Ghiraldi-Lopes, L.D.; Campanerut-Sá, P.A.Z.; Evaristo, G.P.C.; Meneguello, J.E.; Fiorini, A.; Baldin, V.P.; de Souza, E.M.; de Lima Scodro, R.B.; Siqueira, V.L.; Cardoso, R.F. New insights on Ethambutol Targets in *Mycobacterium tuberculosis*. *Infect. Disord. Drug Targets* **2019**, *19*, 73–80. <https://doi.org/10.2174/1871526518666180124140840>.
19. Arun, K.; Madhavan, A.; Abraham, B.; Balaji, M.; Sivakumar, K.; Nisha, P.; Kumar, R.A. Acetylation of isoniazid is a novel mechanism of isoniazid resistance in *Mycobacterium tuberculosis*. *Antimicrob. Agents Chemother.* **2020**, *65*, e00456–e00420. <https://doi.org/10.1128/AAC.00456-20>.
20. Choudhury, M.; Virivinti, J.; Kandi, S.; Sritharan, V.; Sritharan, M. Th2 immune response by the iron-regulated protein HupB of *Mycobacterium tuberculosis*. *Indian J. Tuberc.* **2022**, *69*, 90–99. <https://doi.org/10.1016/j.ijtb.2021.04.011>.
21. Kalra, P.; Mishra, S.K.; Kaur, S.; Kumar, A.; Prasad, H.K.; Sharma, T.K.; Tyagi, J.S. G-quadruplex-forming DNA aptamers inhibit the DNA-binding function of HupB and *Mycobacterium tuberculosis* entry into host cells. *Mol. Ther. Nucleic Acids* **2018**, *13*, 99–109. <https://doi.org/10.1016/j.omtn.2018.08.011>.
22. Sakatos, A.; Babunovic, G.H.; Chase, M.R.; Dills, A.; Leszyk, J.; Rosebrock, T.; Bryson, B.; Fortune, S.M. Posttranslational modification of a histone-like protein regulates phenotypic resistance to isoniazid in mycobacteria. *Sci. Adv.* **2018**, *4*, eaao1478. <https://doi.org/10.1126/sciadv.aao1478>.
23. Green, K.D.; Biswas, T.; Pang, A.H.; Willby, M.J.; Reed, M.S.; Stuchlik, O.; Pohl, J.; Posey, J.E.; Tsodikov, O.V.; Garneau-Tsodikova, S. Acetylation by Eis and deacetylation by Rv1151c of *Mycobacterium tuberculosis* HupB: Biochemical and structural insight. *Biochemistry* **2018**, *57*, 781–790. <https://doi.org/10.1021/acs.biochem.7b01089>.
24. Sharma, D.; Bisht, D. Secretory proteome analysis of streptomycin-resistant *Mycobacterium tuberculosis* clinical isolates. *SLAS Discov.* **2017**, *22*, 1229–1238. <https://doi.org/10.1177/2472555217698428>.
25. Boutte, C.C.; Baer, C.E.; Papavinasundaram, K.; Liu, W.; Chase, M.R.; Meniche, X.; Fortune, S.M.; Sasseti, C.M.; Ioerger, T.R.; Rubin, E.J. A cytoplasmic peptidoglycan amidase homologue controls mycobacterial cell wall synthesis. *Elife* **2016**, *5*, e14590. <https://doi.org/10.7554/eLife.14590>.
26. Weinert, B.; Scholz, C.; Wagner, S.A.; Iesmantavicius, V.; Su, D.; Daniel, J.A.; Choudhary, C. Lysine succinylation is a frequently occurring modification in prokaryotes and eukaryotes and extensively overlaps with acetylation. *Cell Rep.* **2013**, *4*, 842–851. <https://doi.org/10.1016/j.celrep.2013.07.024>.
27. Xie, L.; Liu, W.; Li, Q.; Chen, S.; Xu, M.; Huang, Q.; Zeng, J.; Zhou, M.; Xie, J. First succinyl-proteome profiling of extensively drug-resistant *Mycobacterium tuberculosis* revealed involvement of succinylation in cellular physiology. *J. Proteome Res.* **2015**, *14*, 107–119. <https://doi.org/10.1021/pr500859a>.
28. Zhang, X.; Chen, X.; Wang, B.; Fu, L.; Huo, F.; Gao, T.; Pang, Y.; Lu, Y.; Li, Q. Molecular Characteristic of Both Levofloxacin and Moxifloxacin Resistance in *Mycobacterium tuberculosis* from Individuals Diagnosed with Preextensive Drug-Resistant Tuberculosis. *Microb. Drug Resist.* **2021**, *12*, 280–287. <https://doi.org/10.1089/mdr.2021.0212>.
29. Siregar, T.A.P.; Prombutara, P.; Kanjanasirirat, P.; Kunkaew, N.; Tubsuwan, A.; Boonmee, A.; Palaga, T.; Khumpanied, T.; Borwornpinyo, S.; Chairasert, A. The autophagy-resistant *Mycobacterium tuberculosis* Beijing strain upregulates KatG to evade starvation-induced autophagic restriction. *Pathog. Dis.* **2022**, *80*, ftac004. <https://doi.org/10.1093/femspd/ftac004>.
30. Wei, C.-J.; Lei, B.; Musser, J.M.; Tu, S.-C. Isoniazid activation defects in recombinant *Mycobacterium tuberculosis* catalase-peroxidase (KatG) mutants evident in InhA inhibitor production. *Antimicrob. Agents Chemother.* **2003**, *47*, 670–675. <https://doi.org/10.1128/AAC.47.2.670-675.2003>.
31. Wang, Z.; Xie, J. Phosphoproteomics of *Mycobacterium*-host interaction and inspirations for novel measures against tuberculosis. *Cell. Signal.* **2022**, *91*, 110238. <https://doi.org/10.1016/j.cellsig.2021.110238>.
32. Sherman, D.R.; Grundner, C. Agents of change—concepts in *Mycobacterium tuberculosis* Ser/Thr/Tyr phosphosignalling. *Mol. Microbiol.* **2014**, *94*, 231–241. <https://doi.org/10.1111/mmi.12747>.
33. Kusebauch, U.; Ortega, C.; Ollodart, A.; Rogers, R.S.; Sherman, D.R.; Moritz, R.L.; Grundner, C. *Mycobacterium tuberculosis* supports protein tyrosine phosphorylation. *Proc. Natl. Acad. Sci. USA* **2014**, *111*, 9265–9270. <https://doi.org/10.1073/pnas.1323894111>.
34. Pristic, S.; Husson, R.N. *Mycobacterium tuberculosis* serine/threonine protein kinases. *Microbiol. Spectr.* **2014**, *2*, 2.5. 08. <https://doi.org/10.1128/microbiolspec.MGM2-0006-2013>.
35. Qu, D.; Zhao, X.; Sun, Y.; Wu, F.-L.; Tao, S.-C. *Mycobacterium tuberculosis* Thymidyltransferase RmlA Is Negatively Regulated by Ser/Thr Protein Kinase PknB. *Front. Microbiol.* **2021**, *12*, 643951. <https://doi.org/10.3389/fmicb.2021.643951>.
36. Alsayed, S.S.; Beh, C.C.; Foster, N.R.; Payne, A.D.; Yu, Y.; Gunosewoyo, H. Kinase targets for mycolic acid biosynthesis in *Mycobacterium tuberculosis*. *Curr. Mol. Pharmacol.* **2019**, *12*, 27–49. <https://doi.org/10.2174/1874467211666181025141114.37>.

37. Mori, M.; Sammartino, J.C.; Costantino, L.; Gelain, A.; Meneghetti, F.; Villa, S.; Chiarelli, L.R. An overview on the potential antimycobacterial agents targeting serine/threonine protein kinases from *Mycobacterium tuberculosis*. *Curr. Top. Med. Chem.* **2019**, *19*, 646–661. <https://doi.org/10.2174/1568026619666190227182701>.
38. Hanwarinroj, C.; Thongdee, P.; Sukchit, D.; Taveepanich, S.; Kamsri, P.; Punkvang, A.; Ketrat, S.; Saparpakorn, P.; Hannongbua, S.; Suttisintong, K. In silico design of novel quinazoline-based compounds as potential *Mycobacterium tuberculosis* PknB inhibitors through 2D and 3D-QSAR, molecular dynamics simulations combined with pharmacokinetic predictions. *J. Mol. Graph. Model.* **2022**, *115*, 108231. <https://doi.org/10.1016/j.jmgm.2022.108231>.
39. Wlodarchak, N.; Feltenberger, J.B.; Ye, Z.; Beczkiewicz, J.; Procknow, R.; Yan, G.; King Jr, T.M.; Golden, J.E.; Striker, R. Engineering Selectivity for Reduced Toxicity of Bacterial Kinase Inhibitors Using Structure-Guided Medicinal Chemistry. *ACS Med. Chem. Lett.* **2021**, *12*, 228–235. <https://doi.org/10.1021/acsmmedchemlett.0c00580>.
40. Shamma, F.; Rego, E.H.; Boutte, C.C. Mycobacterial Serine/Threonine phosphatase PstP is phospho-regulated and localized to mediate control of cell wall metabolism. *Mol. Microbiol.* **2022**, *118*, 47–60. <https://doi.org/10.1111/mmi.14951>.
41. Kieser, K.J.; Boutte, C.C.; Kester, J.C.; Baer, C.E.; Barczak, A.K.; Meniche, X.; Chao, M.C.; Rego, E.H.; Sassetti, C.M.; Fortune, S.M. Phosphorylation of the peptidoglycan synthase PonA1 governs the rate of polar elongation in mycobacteria. *PLoS Pathog.* **2015**, *11*, e1005010. <https://doi.org/10.1371/journal.ppat.1005010>.
42. Wang, C.; Zhang, Q.; Tang, X.; An, Y.; Li, S.; Xu, H.; Li, Y.; Wang, X.; Luan, W.; Wang, Y. Effects of CwlM on autolysis and biofilm formation in *Mycobacterium tuberculosis* and *Mycobacterium smegmatis*. *Int. J. Med. Microbiol.* **2019**, *309*, 73–83. <https://doi.org/10.1016/j.ijmm.2018.12.002>.
43. Xu, L.; Wu, D.; Liu, L.; Zheng, Q.; Song, Y.; Ye, L.; Sha, S.; Kang, J.; Xin, Y.; Ma, Y. Characterization of mycobacterial UDP-N-acetylglucosamine enolpyruvyle transferase (MurA). *Res. Microbiol.* **2014**, *165*, 91–101. <https://doi.org/10.1016/j.resmic.2014.01.004>.
44. Bancroft, P.J.; Turapov, O.; Jagatia, H.; Arnvig, K.B.; Mukamolova, G.V.; Green, J. Coupling of peptidoglycan synthesis to central metabolism in mycobacteria: Post-transcriptional control of CWLM by aconitase. *Cell Rep.* **2020**, *32*, 108209. <https://doi.org/10.1016/j.celrep.2020.108209>.
45. Shamma, F.; Papavinasasundaram, K.; Quintanilla, S.Y.; Bandekar, A.; Sassetti, C.; Boutte, C.C. Phosphorylation on PstP regulates cell wall metabolism and antibiotic tolerance in *Mycobacterium smegmatis*. *J. Bacteriol.* **2021**, *203*, e00563–e00520. <https://doi.org/10.1128/JB.00563-20>.
46. Filippova, E.V.; Kieser, K.J.; Luan, C.H.; Wawrzak, Z.; Kiryukhina, O.; Rubin, E.J.; Anderson, W.F. Crystal structures of the transpeptidase domain of the *Mycobacterium tuberculosis* penicillin-binding protein PonA1 reveal potential mechanisms of antibiotic resistance. *FEBS J.* **2016**, *283*, 2206–2218. <https://doi.org/10.1111/febs.13738>.
47. Alsayed, S.S.; Lun, S.; Payne, A.; Bishai, W.R.; Gunosewoyo, H. Facile synthesis and antimycobacterial activity of isoniazid, pyrazinamide and ciprofloxacin derivatives. *Chem. Biol. Drug Des.* **2021**, *97*, 1137–1150. <https://doi.org/10.1111/cbdd.13836>.
48. Prasad, M.S.; Bhole, R.P.; Khedekar, P.B.; Chikhale, R.V. Mycobacterium enoyl acyl carrier protein reductase (InhA): A key target for antitubercular drug discovery. *Bioorg. Chem.* **2021**, *115*, 105242. <https://doi.org/10.1111/cbdd.13836>.
49. Jeffrey North, E.; Jackson, M.; Lee, R.E. New approaches to target the mycolic acid biosynthesis pathway for the development of tuberculosis therapeutics. *Curr. Pharm. Des.* **2014**, *20*, 4357–4378. <https://doi.org/10.2174/1381612819666131118203641>.
50. Li, M.; Huang, Q.; Zhang, W.; Cao, Y.; Wang, Z.; Zhao, Z.; Zhang, X.; Zhang, J. A Novel Acyl-AcpM-Binding Protein Confers Intrinsic Sensitivity to Fatty Acid Synthase Type II Inhibitors in *Mycobacterium smegmatis*. *Front. Microbiol.* **2022**, *13*, 846722. <https://doi.org/10.3389/fmicb.2022.846722>.
51. Marrakchi, H.; Ducasse, S.; Labesse, G.; Montrozier, H.; Margeat, E.; Emorine, L.; Charpentier, X.; Daffé, M.; Quémard, A.K. MabA (FabG1), a *Mycobacterium tuberculosis* protein involved in the long-chain fatty acid elongation system FAS-II. *Microbiology* **2002**, *148*, 951–960. <https://doi.org/10.1099/00221287-148-4-951>.
52. Takayama, K.; Wang, C.; Besra, G.S. Pathway to synthesis and processing of mycolic acids in *Mycobacterium tuberculosis*. *Clin. Microbiol. Rev.* **2005**, *18*, 81–101. <https://doi.org/10.1128/CMR.18.1.81-101.2005>.
53. Veyron-Churlet, R.; Zanella-Cléon, I.; Cohen-Gonsaud, M.; Molle, V.; Kremer, L. Phosphorylation of the *Mycobacterium tuberculosis* β -ketoacyl-acyl carrier protein reductase MabA regulates mycolic acid biosynthesis. *J. Biol. Chem.* **2010**, *285*, 12714–12725. <https://doi.org/10.1074/jbc.M110.105189>.
54. Veyron-Churlet, R.; Molle, V.; Taylor, R.C.; Brown, A.K.; Besra, G.S.; Zanella-Cléon, I.; Fütterer, K.; Kremer, L. The *Mycobacterium tuberculosis* β -ketoacyl-acyl carrier protein synthase III activity is inhibited by phosphorylation on a single threonine residue. *J. Biol. Chem.* **2009**, *284*, 6414–6424. <https://doi.org/10.1074/jbc.M806537200>.
55. Molle, V.; Gulten, G.; Vilchère, C.; Veyron-Churlet, R.; Zanella-Cléon, I.; Sacchettini, J.C.; Jacobs Jr, W.R.; Kremer, L. Phosphorylation of InhA inhibits mycolic acid biosynthesis and growth of *Mycobacterium tuberculosis*. *Mol. Microbiol.* **2010**, *78*, 1591–1605. <https://doi.org/10.1111/j.1365-2958.2010.07446.x>.
56. Walker, T.M.; Kohl, T.A.; Omar, S.V.; Hedge, J.; Elias, C.D.O.; Bradley, P.; Iqbal, Z.; Feuerriegel, S.; Niehaus, K.E.; Wilson, D.J. Whole-genome sequencing for prediction of *Mycobacterium tuberculosis* drug susceptibility and resistance: A retrospective cohort study. *Lancet Infect. Dis.* **2015**, *15*, 1193–1202. [https://doi.org/10.1016/S1473-3099\(15\)00062-6](https://doi.org/10.1016/S1473-3099(15)00062-6).
57. Ando, H.; Miyoshi-Akiyama, T.; Watanabe, S.; Kirikae, T. A silent mutation in mabA confers isoniazid resistance on *Mycobacterium tuberculosis*. *Mol. Microbiol.* **2014**, *91*, 538–547. <https://doi.org/10.1111/mmi.12476>.
58. Vilchère, C.; Jacobs, W.R., Jr. Resistance to isoniazid and ethionamide in *Mycobacterium tuberculosis*: Genes, mutations, and causalities. *Microbiol. Spectr.* **2014**, *2*, 2.4. 01. <https://doi.org/10.1128/microbiolspec.MGM2-0014-2013>.

59. Abrahams, K.A.; Chung, C.-w.; Ghidelli-Disse, S.; Rullas, J.; Rebollo-López, M.J.; Gurcha, S.S.; Cox, J.A.; Mendoza, A.; Jiménez-Navarro, E.; Martínez-Martínez, M.S. Identification of KasA as the cellular target of an anti-tubercular scaffold. *Nat Commun* **2016**, *7*, 12581. <https://doi.org/10.1038/ncomms12581>.
60. Slayden, R.; Barry, C., 3rd. The role of KasA and KasB in the biosynthesis of meromycolic acids and isoniazid resistance in *Mycobacterium tuberculosis*. *Tuberculosis* **2002**, *82*, 149–160. <https://doi.org/10.1054/tube.2002.0333>.
61. Lata, M.; Sharma, D.; Deo, N.; Tiwari, P.K.; Bisht, D.; Venkatesan, K. Proteomic analysis of ofloxacin-mono resistant *Mycobacterium tuberculosis* isolates. *J. Proteom.* **2015**, *127*, 114–121. <https://doi.org/10.1016/j.jprot.2015.07.031>.
62. Warner, D.F.; Rock, J.M.; Fortune, S.M.; Mizrahi, V. DNA replication fidelity in the *mycobacterium tuberculosis* complex. *Adv. Exp. Med. Biol.* **2017**, *1019*, 247–262. https://doi.org/10.1007/978-3-319-64371-7_13.
63. Wipperfman, M.F.; Heaton, B.E.; Nautiyal, A.; Adefisayo, O.; Evans, H.; Gupta, R.; van Ditmarsch, D.; Soni, R.; Hendrickson, R.; Johnson, J. Mycobacterial mutagenesis and drug resistance are controlled by phosphorylation-and cardiolipin-mediated inhibition of the RecA coprotease. *Mol. Cell* **2018**, *72*, 152–161.e7. <https://doi.org/10.1016/j.molcel.2018.07.037>.
64. Lingaraju, S.; Rigouts, L.; Gupta, A.; Lee, J.; Umubyeyi, A.N.; Davidow, A.L.; German, S.; Cho, E.; Lee, J.-i.; Cho, S.-N. Geographic differences in the contribution of ubiA mutations to high-level ethambutol resistance in *Mycobacterium tuberculosis*. *Antimicrob. Agents Chemother.* **2016**, *60*, 4101–4105. <https://doi.org/10.1128/AAC.03002-15>.
65. Sharma, K.; Gupta, M.; Krupa, A.; Srinivasan, N.; Singh, Y. EmbR, a regulatory protein with ATPase activity, is a substrate of multiple serine/threonine kinases and phosphatase in *Mycobacterium tuberculosis*. *FEBS J.* **2006**, *273*, 2711–2721. <https://doi.org/10.1111/j.1742-4658.2006.05289.x>.
66. Sharma, K.; Gupta, M.; Pathak, M.; Gupta, N.; Koul, A.; Sarangi, S.; Baweja, R.; Singh, Y. Transcriptional control of the mycobacterial embCAB operon by PknH through a regulatory protein, EmbR, in vivo. *J. Bacteriol.* **2006**, *188*, 2936–2944. <https://doi.org/10.1128/JB.188.8.2936-2944.2006>.
67. Prieri, M.; Frita, R.; Probst, N.; Sournia-Saquet, A.; Bourotte, M.; Déprez, B.; Baulard, A.R.; Willand, N. Efficient analoging around ethionamide to explore thioamides bioactivation pathways triggered by boosters in *Mycobacterium tuberculosis*. *Eur. J. Med. Chem.* **2018**, *159*, 35–46. <https://doi.org/10.1016/j.ejmech.2018.09.038>.
68. Mugumbate, G.; Mendes, V.; Blaszczyk, M.; Sabbah, M.; Papadatos, G.; Lelievre, J.; Ballell, L.; Barros, D.; Abell, C.; Blundell, T.L. Target identification of *Mycobacterium tuberculosis* phenotypic hits using a concerted chemogenomic, biophysical, and structural approach. *Front. Pharmacol.* **2017**, *8*, 681. <https://doi.org/10.3389/fphar.2017.00681>.
69. Leiba, J.; Carrère-Kremer, S.; Blondiaux, N.; Dimala, M.M.; Wohlkönig, A.; Baulard, A.; Kremer, L.; Molle, V. The *Mycobacterium tuberculosis* transcriptional repressor EthR is negatively regulated by Serine/Threonine phosphorylation. *Biochem. Biophys. Res. Commun.* **2014**, *446*, 1132–1138. <https://doi.org/10.1016/j.bbrc.2014.03.074>.
70. Sun, X.; Ge, F.; Xiao, C.-L.; Yin, X.-F.; Ge, R.; Zhang, L.-H.; He, Q.-Y. Phosphoproteomic analysis reveals the multiple roles of phosphorylation in pathogenic bacterium *Streptococcus pneumoniae*. *J. Proteome Res.* **2010**, *9*, 275–282. <https://doi.org/10.1021/pr900612v>.
71. Sajid, A.; Arora, G.; Gupta, M.; Singhal, A.; Chakraborty, K.; Nandicoori, V.K.; Singh, Y. Interaction of *Mycobacterium tuberculosis* elongation factor Tu with GTP is regulated by phosphorylation. *J. Bacteriol.* **2011**, *193*, 5347–5358. <https://doi.org/10.1128/JB.05469-11>.
72. Singhal, A.; Arora, G.; Sajid, A.; Maji, A.; Bhat, A.; Virmani, R.; Upadhyay, S.; Nandicoori, V.K.; Sengupta, S.; Singh, Y. Regulation of homocysteine metabolism by *Mycobacterium tuberculosis* S-adenosylhomocysteine hydrolase. *Sci. Rep.* **2013**, *3*, 2264. <https://doi.org/10.1038/srep02264>.
73. Corrales, R.M.; Leiba, J.; Cohen-Gonsaud, M.; Molle, V.; Kremer, L. *Mycobacterium tuberculosis* S-adenosyl-L-homocysteine hydrolase is negatively regulated by Ser/Thr phosphorylation. *Biochem. Biophys. Res. Commun.* **2013**, *430*, 858–864. <https://doi.org/10.1016/j.bbrc.2012.11.038>.
74. Argyrou, A.; Jin, L.; Siconilfi-Baez, L.; Angeletti, R.H.; Blanchard, J.S. Proteome-wide profiling of isoniazid targets in *Mycobacterium tuberculosis*. *Biochemistry* **2006**, *45*, 13947–13953. <https://doi.org/10.1021/bi061874m>.
75. Wehenkel, A.; Bellinzoni, M.; Graña, M.; Duran, R.; Villarino, A.; Fernandez, P.; Andre-Leroux, G.; England, P.; Takiff, H.; Cerveñansky, C. Mycobacterial Ser/Thr protein kinases and phosphatases: Physiological roles and therapeutic potential. *Biochim. Biophys. Acta Proteins Proteom.* **2008**, *1784*, 193–202. <https://doi.org/10.1016/j.bbapap.2007.08.006>.
76. Ge, P.; Lei, Z.; Yu, Y.; Lu, Z.; Qiang, L.; Chai, Q.; Zhang, Y.; Zhao, D.; Li, B.; Pang, Y. *M. tuberculosis* PknG manipulates host autophagy flux to promote pathogen intracellular survival. *Autophagy* **2021**, *7*, 576–594. <https://doi.org/10.1080/15548627.2021.1938912>.
77. Xu, W.; DeJesus, M.A.; Rücker, N.; Engelhart, C.A.; Wright, M.G.; Healy, C.; Lin, K.; Wang, R.; Park, S.W.; Ioerger, T.R. Chemical genetic interaction profiling reveals determinants of intrinsic antibiotic resistance in *Mycobacterium tuberculosis*. *Antimicrob. Agents Chemother.* **2017**, *61*, e01334–e01317. <https://doi.org/10.1128/AAC.01334-17>.
78. Bellinzoni, M.; Wehenkel, A.M.; Durán, R.; Alzari, P.M. Novel mechanistic insights into physiological signaling pathways mediated by mycobacterial Ser/Thr protein kinases. *Genes Immun.* **2019**, *20*, 383–393. <https://doi.org/10.1038/s41435-019-0069-9>.
79. Torfs, E.; Piller, T.; Cos, P.; Cappoen, D. Opportunities for overcoming *Mycobacterium tuberculosis* drug resistance: Emerging mycobacterial targets and host-directed therapy. *Int. J. Mol. Sci.* **2019**, *20*, 2868. <https://doi.org/10.3390/ijms20122868>.
80. Nakedi, K.C.; Calder, B.; Banerjee, M.; Giddey, A.; Nel, A.J.; Garnett, S.; Blackburn, J.M.; Soares, N.C. Identification of novel physiological substrates of *Mycobacterium bovis* BCG protein kinase G (PknG) by label-free quantitative phosphoproteomics. *Mol. Cell Proteom.* **2018**, *17*, 1365–1377. <https://doi.org/10.1074/mcp.RA118.000705>.

81. Iqbal, I.K.; Bajeli, S.; Akela, A.K.; Kumar, A. Bioenergetics of Mycobacterium: An emerging landscape for drug discovery. *Pathogens* **2018**, *7*, 24. <https://doi.org/10.3390/pathogens7010024>.
82. Wagner, T.; André-Leroux, G.; Hindie, V.; Barilone, N.; Lisa, M.-N.; Hoos, S.; Raynal, B.; Vulliez-Le Normand, B.; O'hare, H.M.; Bellinzoni, M. Structural insights into the functional versatility of an FHA domain protein in mycobacterial signaling. *Sci. Signal.* **2019**, *12*, 9504. <https://doi.org/10.1126/scisignal.aav9504>.
83. Ventura, M.; Rieck, B.; Boldrin, F.; Degiacomi, G.; Bellinzoni, M.; Barilone, N.; Alzaidi, F.; Alzari, P.M.; Manganelli, R.; O'Hare, H.M. GarA is an essential regulator of metabolism in *Mycobacterium tuberculosis*. *Mol. Microbiol.* **2013**, *90*, 356–366. <https://doi.org/10.1111/mmi.12368>.
84. Kohanski, M.A.; Dwyer, D.J.; Collins, J. How antibiotics kill bacteria: From targets to networks. *Nat. Rev. Microbiol.* **2010**, *8*, 423–435. <https://doi.org/10.1038/nrmicro2333>.
85. Wolff, K.A.; de la Peña, A.H.; Nguyen, H.T.; Pham, T.H.; Amzel, L.M.; Gabelli, S.B.; Nguyen, L. A redox regulatory system critical for mycobacterial survival in macrophages and biofilm development. *PLoS Pathog.* **2015**, *11*, e1004839. <https://doi.org/10.1371/journal.ppat.1004839>.
86. Kidwai, S.; Bouzeyen, R.; Chakraborti, S.; Khare, N.; Das, S.; Priya Gosain, T.; Behura, A.; Meena, C.L.; Dhiman, R.; Essafi, M. NU-6027 inhibits growth of *Mycobacterium tuberculosis* by targeting protein kinase D and protein kinase G. *Antimicrob. Agents Chemother.* **2019**, *63*, e00996–e00919. <https://doi.org/10.1128/AAC.00996-19>.
87. Singhal, A.; Arora, G.; Virmani, R.; Kundu, P.; Khanna, T.; Sajid, A.; Misra, R.; Joshi, J.; Yadav, V.; Samanta, S. Systematic analysis of mycobacterial acylation reveals first example of acylation-mediated regulation of enzyme activity of a bacterial phosphatase. *J. Biol. Chem.* **2015**, *290*, 26218–26234. <https://doi.org/10.1074/jbc.M115.687269>.
88. Choukate, K.; Chaudhuri, B. Structural basis of self-assembly in the lipid-binding domain of mycobacterial polar growth factor Wag31. *IUCrJ* **2020**, *7*, 767–776. <https://doi.org/10.1107/S2052252520006053>.
89. Singh, V.; Dhar, N.; Pató, J.; Kolly, G.S.; Korduláková, J.; Forbak, M.; Evans, J.C.; Székely, R.; Rybníček, J.; Palčková, Z. Identification of aminopyrimidine-sulfonamides as potent modulators of Wag31-mediated cell elongation in mycobacteria. *Mol. Microbiol.* **2017**, *103*, 13–25. <https://doi.org/10.1111/mmi.13535>.
90. Birhanu, A.G.; Gómez-Muñoz, M.; Kalayou, S.; Riaz, T.; Lutter, T.; Yimer, S.A.; Abebe, M.; Tønrum, T. Proteome Profiling of *Mycobacterium tuberculosis* Cells Exposed to Nitrosative Stress. *ACS Omega.* **2022**, *7*, 3470–3482. <https://doi.org/10.1021/acsomega.1c05923>.